Can You Take Cymbalta And Wellbutrin Together? (+3 Benefits)

By Ivan Kahwa

Page last updated: 02/02/2024 | Next review date: 02/02/2026

Author bio

Mr Ivan Kahwa is a chemist and phytopharmaceutical scientist with expertise in chemistry, pharmacology, phytochemistry, and Nanobiotechnology. He writes and reviews content on these topics.

Mr Ivan Kahwa’s Highlights:

Guest Researcher at the University of Leipzig, Senior Research Fellow/Scientist, and Lecturer at the Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology.

Professional Experience:

Mr Ivan joined PHARMBIOTRAC as a research fellow/scientist during his master of science tenure. He contributed to the development of most of the phytopharmaceutical products in the project. Furthermore, he participated in carrying out the pharmacological activities of the developed products in laboratory animals such as mice and rats in order to develop proper doses hence leading to pre-clinical studies.

With the above relevant research experience, Ivan started to work with the University of Leipzig on collaborative projects with Mbarara University to develop the chemistry of Ugandan Medicinal plants and their pharmacological activities. This was coupled with several consultative positions by different German NGOs. Mr. Kahwa is also a supporting in the teaching and learning at the Departments of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, Mbarara University of Science and Technology.

With the increase in antimicrobial resistance globally, Ivan retooled his thinking towards developing new naturally derived antibiotic regimens from Ugandan propolis with the assistance of nanotechnology to improve their delivery to microbial cells. Kahwa has also published over 28 articles in peer-reviewed journals and he is currently reviewing for many journals.

Education:

2023-2027: PhD in Pharmaceutical Sciences (ongoing) with a focus on Pharmaceutical Microbiology and Nanobiology at Mbarara University of Science and Technology.

2022: 2Msc. in Pharmacognosy and Natural Medicine Science at Mbarara University of Science and Technology.

2018: Bachelor of Science (Chemistry) at Mbarara University of Science and Technology.

Publications:

▪ Iqbal, S., Jabeen, F., Kahwa, I., & Omara, T. 2023. Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-023-09804-7

▪ Gupta, A. K., Yadav, R., Sharma, S., Sawale, J., & Kahwa, I. 2023. Anti-ageing Activity and Antioxidant Activity of Methanol Extracts of Leaves and Flowers of Salvia officinalis and Rosmarinus officinalis. Journal of Young Pharmacists, 15(3), 448–455. https://doi.org/10.5530/jyp.2023.15.60

▪ Tolo, C.U., Kahwa, I., Nuwagira, U., Weisheit, A. and Ikiriza, H., 2023. Medicinal plants used in treatment of various diseases in the Rwenzori Region, Western Uganda. Ethnobotany Research and Applications, 25, pp.1-16.

https://ethnobotanyjournal.org/index.php/era/article/view/4683

▪ Kahwa, I., Ajayi, C.O., Yadav, R., Chauhan, N.S., Shah, K., Abdelgadir, A.A., Shegena, E.A., Daniel, S., Omara, T., Asiimwe, J.B. and Ikiriza, H., 2023. Pharmacognostic and phytochemical studies as an invaluable approach for correct identification of medicinal plants: The case of Artemisia vulgaris L. substituted for Artemisia annua L. in Western Uganda. TMR Integr Med, 7, p.e23004.

https://doi.org/10.53388/TMRIM202307004

▪ Nalimu, F., Oloro, J., Kahwa, I. and Ogwang, P.E., 2021. Review on the phytochemistry and toxicological profiles of Aloe vera and Aloe ferox. Future Journal of Pharmaceutical Sciences, 7, pp.1-21.

https://doi.org/10.1186/s43094-021-00296-2

▪ Elamin, O.H.S., Ali, M.A., Elgezuli, I.A.A., Bashir, M.A. and Kahwa, I., 2021. Diagnosis of pre-and post-treatment of echinococcus granulosus with counter current immune electrophoresis and bacterial co-agglutination. Journal of Microbiology and Infectious Diseases, 11(02), pp.88-94.

https://doi.org/10.5799/jmid.951600

Published book Chapter

▪ Kahwa, I., Ayesiga, I., Nakalema, S., Alinaiswe, R., Mbabazi, R. and Iqbal, S., 2023. Natural products in the management of onchocerciasis. In Natural Products in Vector-Borne Disease Management (pp. 63-80). Academic Press. Book Chapter.

https://doi.org/10.1016/B978-0-323-91942-5.00012-4

Submitted manuscripts Under Review:

▪ Comparison of the Wound Healing Activity of the Leaf and Leaf Ash Extracts of Vernonia amygdalina in Rats. Journal name: Clinical Phytoscience

▪ Ethnobotanical Survey of Medicinal plants used in the management of cancer in Uganda. Journal name: Journal of Herbal Medicine

▪ Ethnobotanical survey and phytochemical screening of medicinal plants used in treatment of epilepsy by PROMETRA-Uganda Traditional Health Practitioners in Mpigi District, Uganda. Journal name: Journal of Ethnopharmacology

Submitted book chapters under review

1.Book title: Algae as a Natural Solution for Water-Food-Energy Nexus, Section 4: Microalgae and cyanobacteria for food applications, Chapter 4.6: Safety, toxicological and allergenic aspects of using algae for food. Authors: Christine Kyarimpa, Tom Omute, Caroline K. Nakiguli, Alice V. Khanakwa4, Christopher Angiro, Ivan Kahwa, Fortunate Ahumuza, Timothy Omara*. Publisher: Springer Nature Singapore Pte Ltd. 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore.

2.Book title: Nutraceuticals Inspiring the Contemporary Therapy for Lifestyle Diseases. Chapter: Nutraceutical applications of Seaweeds and their Phytocompounds in Nutrition and Treatment of Diseases. Authors: Ivan Kahwa, Timothy Omara , Innocent Ayesiga , Gael Noel Neh Neba Ambe , Zehbanaz Javidbhai Panwala , Rachel Mbabazi , Shabnoor Iqbal , Christine Kyarimpa , Christine Betty Nagawa , Kamal Shah ,Nagendra Singh Chauhan* Publisher: CRC Press

You can view my works on the following professional sites:

Research Gate: https://www.researchgate.net/profile/Ivan-Kahwa

Google Scholar: https://scholar.google.com/citations?user=tOwrvqoAAAAJ&hl=en

ORCID: https://orcid.org/0000-0002-6440-3437

Linkedin: https://de.linkedin.com/in/ivan-kahwa-865450159

Ivan Kahwa

View More north_east

In this article, we will explore the combination of Cymbalta and Wellbutrin. We will also discuss the research studies suggesting the reported benefits and side effects of taking these medications together.

Can you take Cymbalta and Wellbutrin together?

Yes, you can take Cymbalta and Wellbutrin together. According to research, combining Cymbalta and Wellbutrin in low doses has shown potential for enhancing the effectiveness of these medications in treating various mental disorders, however, the combination of drugs may also cause side effects in some individuals.

Cymbalta belongs to the class of serotonin and norepinephrine reuptake inhibitors. It helps in the regulation of mood in individuals with underlying mental disorders such as anxiety and depression. Additionally, Cymbalta is also effective in the management of fibromyalgia and chronic pain (1).

On the other hand, Wellbutrin belongs to the class of drugs known as atypical antidepressants and works by affecting certain neurotransmitters in the brain, particularly norepinephrine, and dopamine. It is commonly used to manage the symptoms associated with depression and anxiety (2).

What does research suggest?

In a research study, the use of Cymbalta and Wellbutrin for managing depression was analyzed for one month. The evaluation after this period demonstrated the effectiveness of this combination in alleviating depressive symptoms. However, some patients experienced mild to moderate side effects, including nausea, dizziness, agitation, tiredness, and headaches (3).

A research study demonstrated that the combination of Cymbalta and Wellbutrin induced delirium in a patient undergoing this treatment for depression. Delirium symptoms emerged approximately one week after adding Wellbutrin to the existing Cymbalta regimen. The symptoms gradually subsided within a few days after discontinuing Wellbutrin (4).

The combination of Cymbalta and Wellbutrin led to elevated hydroxybupropion levels by inhibiting CYP450 enzymes responsible for the metabolism of Wellbutrin. The increased levels of this metabolite resulted in elevated dopamine levels in the brain, contributing to the development of delirium (4).

What are the benefits of combining Cymbalta and Wellbutrin?

The combination of Cymbalta and Wellbutrin may offer benefits to certain individuals who suffer from depression. A healthcare professional should make the decision to use this combination after considering the individual’s specific needs and medical history.

The combination of these medications may lead to a more comprehensive approach to managing depression due to their different mechanisms of action. The combination may help manage a range of symptoms associated with mental disorders.

In some cases, using a combination of medications at lower doses may help minimize side effects compared to using higher doses of a single medication.

It’s important to note that individual responses to medications vary, and potential benefits should be weighed against potential risks. Regular monitoring and communication with a healthcare provider are essential to ensure the optimal treatment plan and address any emerging concerns.

What are the side effects of combining Wellbutrin and Cymbalta?

The concurrent use of Cymbalta and Wellbutrin may lead to some adverse effects such as (3),

vomiting
delirium
hallucinations
fatigue
agitation
aggression
confusion
dizziness
jitteriness
sleep disturbances
weight gain
hyperhidrosis
drowsiness

Consult your doctor if you experience any unwanted side effects associated with the use of this combination.

Considerations before taking Cymbalta and Wellbutrin together

Always consult your healthcare professional before using these medications together. The combination of these antidepressant medications should only be taken under the guidance of a qualified healthcare professional.

Inform your healthcare provider about all medications you are taking, including non-prescription drugs as certain medications may interact with Cymbalta or Wellbutrin.

These interactions could impact the therapeutic benefits of the medications or elevate the risk of adverse effects. Open communication with your healthcare provider is essential for ensuring the safe and optimal use of these medications.

Be sure to provide a thorough history of your medical conditions, including any history of seizures, liver problems, or other mental conditions. It is important to note that Wellbutrin has a lower seizure threshold, and this risk may increase when combined with certain medications.

You should be vigilant for any side effects and report them promptly to your healthcare provider. The side effects may differ from those experienced with each medication alone, so it is important to keep track of how you are feeling.

Remember, the decision to combine medications should be made collaboratively with your healthcare provider based on a comprehensive evaluation of your health. Open communication about your experiences and any concerns is vital for effective treatment.

In my opinion, the combination of Cymbalta and Wellbutrin is effective in the management of treatment-resistant mental disorders such as depression. However, this combination should only be used only the guidance and supervision of a healthcare professional to ensure the safety and efficacy of treatment.

Was this helpful?

Thanks for your feedback!

References

1.-

Dhaliwal JS, Spurling BC, Molla M. Duloxetine. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31747213. ahttps://pubmed.ncbi.nlm.nih.gov/31747213/

2.-

Khan SR, Berendt RT, Ellison CD, Ciavarella AB, Asafu-Adjaye E, Khan MA, Faustino PJ. Bupropion Hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2016;41:1-30. doi: 10.1016/bs.podrm.2015.12.001. Epub 2016 Feb 17. PMID: 26940167. https://pubmed.ncbi.nlm.nih.gov/26940167/

3.-

Papakostas GI, Worthington JJ 3rd, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006;23(3):178-81. doi: 10.1002/da.20181. PMID: 16528701. https://pubmed.ncbi.nlm.nih.gov/16528701/

4.-

Ma SP, Tsai CJ, Chang CC, Hsu WY. Delirium associated with concomitant use of duloxetine and bupropion in an elderly patient. Psychogeriatrics. 2017 Mar;17(2):130-132. doi: 10.1111/psyg.12202. Epub 2016 Apr 5. PMID: 27046219. https://pubmed.ncbi.nlm.nih.gov/27046219/

Pharmaceuticals and Medications

Diseases & Conditions

Can you take Cymbalta and Wellbutrin together? (+3 benefits)